Consider Eurofins DiscoverX’s custom development capabilities for custom cell lines, assays, & enzyme development.
Checkpoint Receptor Assays
Accelerate Cancer Immunotherapy Drug Development with Easy-to-use, Functional Cell-based Assays
Regulation of immune responses is tightly controlled through a balance of co-stimulatory and inhibitory checkpoint receptors often exploited by many cancers. Therefore, therapeutics that block inhibitory receptors or activate immune-stimulatory checkpoint receptors, such as PD-1 receptor, have proven to be powerful agents to restore anti-tumor immune responses.
Eurofins DiscoverX® offers a large, diverse selection of assays for characterization, screening, and potency QC lot-release testing of immunotherapy therapeutics targeting both inhibitory and co-stimulatory checkpoint receptors. Utilize PathHunter® functional, mechanism of action (MOA)-reflective cell-based checkpoint receptor assays to analyze signaling, dimerization, internalization, and clustering/crosslinking of checkpoint receptors. These simple, rapid assays provide a highly sensitive response for most targets without primary cells or complex protocols in a few hours for most targets without primary cells or complex protocols.
Product Highlights
- Biologically-Relevant — MOA-reflective, functional assays for monitoring checkpoint signaling and testing of small molecule or biologic therapeutics
- Comprehensive Portfolio — Large menu of off-the-shelf assays for accelerating assay development and implementation time
- Robust Assays – Highly reproducible assays for potency and lot-release applications for immunotherapy drug discovery and development
- Simple Protocol, Fast Results — Easy-to-run, rapid homogeneous protocol amenable to implementation in multiple labs and high-throughput format for increased efficiency
Checkpoint Agonist Antibody Assays
Mechanistically relevant cell-based agonist antibody assays to evaluate and characterize agonism of antibodies targeting checkpoint receptors for immu...Show More
Products
Targets
Highlights
Workflow
Assay Principles
Applications
Resources
Related Pages
Products
PathHunter checkpoint assays are available as complete ready-to-use bioassay kits and stable cell lines formats for checkpoint receptor dimerization, signaling, clustering, and internalization assessment. For additional checkpoint receptor cell lines not shown below, please contact custom assay development (CAD) for more information.
Product Types
- Checkpoint Receptor Bioassay Kits – Ready-to-use cell-based assay kits with a simple, homogenous protocol and are provided as qualified or target-based. These physiologically relevant, robust bioassays are fit-for-purpose for use in screening and characterization applications to potency testing in quality control lot-release programs. Learn more about Bioassay Kits.
- Checkpoint Receptor eXpress Assay Kits – Ready-to-use cell-based assay kits for quick analysis and implementation in early discovery phases for screening applications, proof-of-concept, mechanism of action confirmation, and rank-ordering studies. Learn more about eXpress Assay Kits.
- Checkpoint Receptor Cell Lines – Stable cell lines developed to reflect the target’s mechanism of action with a drug interaction in a standard cell line background. Learn more about Stable Cell Lines.
Applications
- Checkpoint Receptor Signaling Assays – Assays for screening therapeutics and quantifying the activation and inhibition of various signaling pathways.
- Checkpoint Receptor Dimerization Assays – Assays to study receptor dimerization and analyze the pharmacological effects of therapeutics on this event.
- Checkpoint Receptor Internalization Assays – Translocation assays to study receptor internalization and analyze the pharmacological effects of therapeutics on this event. Learn more about Translocation Assays.
- Checkpoint Receptor Cytotoxicity Assays – KILR® assays to measure target cell death via several mechanisms of action. Learn more about KILR Cytotoxicity Assays.
- Checkpoint Receptor Clustering Assays – Unique assays to study antibody-based therapeutics through antibody-mediated cross-linking by FcγR clustering.
Early Access
Eurofins DiscoverX helps accelerate the entry of your therapeutic molecule to market for the latest and most researched targets with a list of early access cell lines and ready-to-use assay kits.
| Target | Assay Measures | Cat. No. |
|---|---|---|
| PD-1/LAG3 | Receptor Dimerization | Inquire |
| PD-1/CTLA4 | Receptor Dimerization | Inquire |
| PD-1/TIGIT | Receptor Dimerization | Inquire |
| PD-L1/TIM3 | Receptor Dimerization | Inquire |
| PD-1/PD-L1 | Receptor Dimerization | Inquire |
| PD-L1/CTLA4 | Receptor Dimerization | Inquire |
| PD-1/CEACAM1 | Receptor Dimerization | Inquire |
| TIM3/CEACAM1 | Receptor Dimerization | Inquire |
| TIGIT/LAG3 | Receptor Dimerization | Inquire |
| PD-1/CD28 | Receptor Dimerization | Inquire |
| mPD-1/mLAG3 | Receptor Dimerization | Inquire |
| mPD-1/mTIGIT | Receptor Dimerization | Inquire |
| mPD-1/mCTLA4 | Receptor Dimerization | Inquire |